{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T13:24:37Z","timestamp":1792329877119,"version":"4.4.0"},"reference-count":20,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Tirzepatide reduces HbA1c and body weight, and creatinine-based estimated glomerular filtration rate (eGFR) decline. Unlike creatine-derived eGFR (eGFR-creatinine), cystatin C\u2013derived eGFR (eGFR-cystatin C) is unaffected by muscle mass changes. We assessed effects of tirzepatide on eGFR-creatinine and eGFR-cystatin C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Our primary outcome was eGFR change from baseline at 52 weeks with pooled tirzepatide (5, 10, and 15 mg) and titrated insulin glargine in adults with type 2 diabetes and high cardiovascular risk (SURPASS-4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Least squares mean (SE) eGFR-creatinine (mL\/min\/1.73 m2) changes from baseline with tirzepatide and insulin glargine were \u22122.5 (0.38) and \u22123.9 (0.38) (between-group difference, 1.4 [95% CI 0.3\u20132.4]) and \u22123.5 (0.37) and \u22125.3 (0.37) (between-group difference, 1.8 [95% CI 0.8\u20132.8]) for eGFR-cystatin C. Baseline, 1-year, and 1-year change from baseline values significantly correlated between eGFR-cystatin C and eGFR-creatinine. Measures of eGFR changes did not correlate with body weight changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Tirzepatide slows the eGFR decline rate, supporting a kidney-protective effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc23-0261","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T15:21:06Z","timestamp":1685719266000},"page":"1501-1506","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":51,"title":["Effects of Tirzepatide Versus Insulin Glargine on Cystatin C\u2013Based Kidney Function: A SURPASS-4 Post Hoc Analysis"],"prefix":"10.2337","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"first","affiliation":[{"name":"1Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"},{"name":"2The George Institute for Global Health, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"3School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"Pavo","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haupt","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Duffin","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Yang","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Wiese","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hemmingway","sequence":"additional","affiliation":[{"name":"4Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"5Division of Nephrology, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"6Providence Health Care, University of Washington, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"2023072018562287500_B1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2023072018562287500_B2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023072018562287500_B3","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"2023072018562287500_B4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12882-017-0474-0","article-title":"Effect of large weight reductions on measured and estimated kidney function","volume":"18","author":"von Scholten","year":"2017","journal-title":"BMC Nephrol"},{"key":"2023072018562287500_B5","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41591-019-0627-8","article-title":"Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease","volume":"25","author":"Lees","year":"2019","journal-title":"Nat Med"},{"key":"2023072018562287500_B6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023072018562287500_B7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"2023072018562287500_B8","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023072018562287500_B9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once eeekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2023072018562287500_B10","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.34067\/KID.0003202022","article-title":"Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR","volume":"3","author":"Chen","year":"2022","journal-title":"Kidney360"},{"key":"2023072018562287500_B11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2021.08.036","article-title":"The difference between cystatin C- and creatinine-based eGFR is associated with adverse cardiovascular outcome in patients with chronic kidney disease","volume":"335","author":"Kim","year":"2021","journal-title":"Atherosclerosis"},{"key":"2023072018562287500_B12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.ajkd.2020.05.018","article-title":"The difference between cystatin c- and creatinine-based estimated GFR and incident frailty: an analysis of the Cardiovascular Health Study (CHS)","volume":"76","author":"Potok","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023072018562287500_B13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023072018562287500_B14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","article-title":"Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)","volume":"21","author":"Tuttle","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2023072018562287500_B15","doi-asserted-by":"crossref","first-page":"e0163907","DOI":"10.1371\/journal.pone.0163907","article-title":"Effects of bariatric surgery on renal function in obese patients: a systematic review and meta analysis","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"2023072018562287500_B16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","article-title":"Measurement and estimation of GFR for use in clinical practice: Core Curriculum 2021","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2023072018562287500_B17","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2023072018562287500_B18","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/cvr\/cvab357","article-title":"Contributions of obesity to kidney health and disease: insights from Mendelian randomization and the human kidney transcriptomics","volume":"118","author":"Xu","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2023072018562287500_B19","doi-asserted-by":"crossref","first-page":"k5301","DOI":"10.1136\/bmj.k5301","article-title":"Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium","volume":"364","author":"Chang","year":"2019","journal-title":"BMJ"},{"key":"2023072018562287500_B20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1681\/ASN.2020050679","article-title":"Conventional and genetic evidence on the association between adiposity and CKD","volume":"32","author":"Zhu","year":"2021","journal-title":"J Am Soc Nephrol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/8\/1501\/729636\/dc230261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/46\/8\/1501\/729636\/dc230261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T14:58:17Z","timestamp":1689865097000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/46\/8\/1501\/151477\/Effects-of-Tirzepatide-Versus-Insulin-Glargine-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,2]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-0261","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.22817039","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.22817039.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.2337\/figshare.22817039","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.22817039.v1","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}